ARTICLE | Politics & Policy
Kymriah deal to stay despite CMS shift on proposed pilot
July 9, 2018 10:36 PM UTC
Novartis AG (NYSE:NVS; SIX:NOVN) said Monday an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a demonstration program including indication-based pricing.
A CMS spokesperson told BioCentury Monday the agency "reviewed Novartis’s proposed demonstration and then decided to go in a different direction," but declined to provide details...
BCIQ Company Profiles